FENNEC PHARMACEUTICALS INC.
Fennec Pharmaceuticals is a commercial-stage specialty pharmaceutical company focused on preventing cisplatin-induced ototoxicity, or hearing damage, in pediatric patients with localized, non-metastatic solid tumors. Its product, PEDMARK®, is an intravenous sodium thiosulfate treatment approved in the United States and Europe for eligible pediatric patients one month of age and older. In Europe, the U.K., Australia and New Zealand, the product is branded PEDMARQSI®. Fennec sells PEDMARK® in the United States through a field force and supports patient access through its Fennec HEARS® program. It earns money from product sales and licensing arrangements: Norgine commercializes PEDMARQSI® in Europe, Australia and New Zealand, while Inpharmus handles certain regulatory, commercialization and distribution activities in Turkey and Gulf Cooperation Council countries. Fennec supplies the product under the Inpharmus agreement. The company is headquartered in Research Triangle Park, North Carolina.
No SEC Form 4 filings for $FENC in the last 30 days.
See all $FENC insider activity →Fennec Pharmaceuticals reported Q3 2026 net product sales of $19.4M, up 56% year over year, and non-GAAP adjusted EBITDA of $5.8M. The company had $6.7M in cash from operations and $48.7M in quarter-end cash, according to the press release.
FENNEC PHARMACEUTICALS INC. (FENC) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Fennec Pharmaceuticals Announces ORAL PRESENTATION OF DETAILED Results From Investigator-Initiated Phase 2 STS-J01 Clinical Study of PEDMARK ® in Japan AT SIOP 2026 ~ Primary Endpoint Met: American Speech-Language-Hearing Association (ASHA)-Defined Hearing Loss Occ
Fennec Pharmaceuticals (FENC) will present detailed Phase 2 Pedmark trial results at SIOP 2026. The study evaluated Pedmark's ability to reduce cisplatin-induced hearing loss in Japanese pediatric patients. Pedmark is FDA-approved for this indication. FENC stock is up 2.75% at $10.84.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning FENC (FENNEC PHARMACEUTICALS INC.). Coverage has skewed bullish: 3 bullish, 1 neutral, and 0 bearish.
Recent FENC coverage spans earnings, corporate actions and insider activity.
Strong top‑line growth and cash generation suggest positive market reaction.
Positive trial data could boost stock on anticipated regulatory filing and partnership interest.
Potential positive impact if data are favorable; neutral until results released.
Insider sale may signal reduced confidence or portfolio rebalancing, modest negative pressure on the stock.
Insider sale may signal CFO's view on near-term valuation.
AlphAI scores every news story that mentions FENC with an AI model for sentiment and relevance, and aggregates insider trades from FENNEC PHARMACEUTICALS INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Fennec Pharmaceuticals reported Q3 2026 net product sales of $19.4M, up 56% year over year, and non-GAAP adjusted EBITDA of $5.8M. The company had $6.7M in cash from operations and $48.7M in quarter-end cash, according to the press release.
FENNEC PHARMACEUTICALS INC. (FENC) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Fennec Pharmaceuticals Announces ORAL PRESENTATION OF DETAILED Results From Investigator-Initiated Phase 2 STS-J01 Clinical Study of PEDMARK ® in Japan AT SIOP 2026 ~ Primary Endpoint Met: American Speech-Language-Hearing Association (ASHA)-Defined Hearing Loss Occ
Fennec Pharmaceuticals (FENC) will present detailed Phase 2 Pedmark trial results at SIOP 2026. The study evaluated Pedmark's ability to reduce cisplatin-induced hearing loss in Japanese pediatric patients. Pedmark is FDA-approved for this indication. FENC stock is up 2.75% at $10.84.
Sayad Pierre Sargis (Chief Medical Officer) sold 12,000 shares of FENNEC PHARMACEUTICALS INC. (FENC) at $12.18 ($0.15M total) on 2026-08-31.
Andrade Robert (CHIEF FINANCIAL OFFICER) sold 75,000 shares of FENNEC PHARMACEUTICALS INC. (FENC) at $11.78 ($0.88M total) on 2026-08-27 under a Rule 10b5-1 trading plan.
Fennec Pharmaceuticals (NASDAQ:FENC) reported Q2 results on an earnings call. Net product sales were $17.1 million, up 78% year over year. Non-GAAP adjusted EBITDA was $2.8 million versus a $1.2 million loss a year earlier. Cash and cash equivalents were $41.2 million at June 30, 2026. Management cited PEDMARK momentum and no quantitative 2026 revenue outlook.
Fennec Pharmaceuticals (NASDAQ:FENC) shares rose about 8% premarket after Q2 results beat estimates. Adjusted EPS was $0.05 vs $0.02 consensus. Revenue was $17.87M vs $16.39M forecast. Net product sales for PEDMARK grew 78% to $17.1M. Adjusted EBITDA turned positive at $2.8M vs a $1.2M loss. Cash was $41.2M.
Insider Monkey highlights nine companies that beat Q2 EPS expectations among 350+ firms reporting by Aug. 11. Reported EPS surprises include RideNow Group (RDNW) $0.16 vs $0.13, Anterix (ATEX) $0.01 vs -$0.17, Super Micro Computer (SMCI) $1.70 vs $0.96, and Fennec Pharmaceuticals (FENC) $0.05 vs $0.01. The rest of the piece shifts to AI themes and promotional content.
Biotech stocks hit 52-week highs Aug. 7, 2026. Halozyme (HALO) rose 20% after Q2 revenue of $481M (+48% Y/Y) and 2026 revenue guidance of $1.83B-$1.91B. Fennec (FENC) reached $11.66 on PEDMARK sales of $15.1M (+71% Y/Y). Avalyn (AVLN) hit $34.15. Amylyx (AMLX) hit $24.60. Chemed (CHE) rose to $552.72 after Q2 revenue $673M (+8.8%) and 2026 growth guidance of 8.25%-9.25%.
FENNEC PHARMACEUTICALS INC. (FENC) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001211583 0001211583 2026-06-10 2026-06-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
